After a previous rejection and a discount offer, Roche's immunotherapy Tecentriq snagged an OK from England's influential cost-effectiveness watchdogs.
The cost-effectiveness gatekeeper figures Dupixent works—and offers an option for patients who really need one—but isn't sure it's worth the price.
Impax Laboratories will sell its manufacturing site in Taiwan to Bora Pharmaceuticals for $18.5 million and take a charge of up to $80 million.
Cost watchdogs in England and pharma don't always agree, but the sides are celebrating two new deals on Merck KGaA's Mavenclad and Roche's Perjeta.
Ovarian cancer patients who respond to chemo have new treatment options, but a cost watchdog isn’t convinced they're worth the price.
Bringing a new oncology drug to market in the U.S. is expensive, but cost efficiencies can be wrought, especially with multiple indications.
Three months ago, England’s cost watchdogs nixed Sanofi's Gaucher treatment Cerdelga. But they're already singing a different tune.
Just days after announcing plans to ax 500 jobs in Switzerland, Novartis said another 250 jobs will be eliminated in the U.S.
The world's best-selling drug, AbbVie's Humira, isn’t worth its current net price—and isn’t as good at its job as two potential competitors. That’s ICER's conclusion after reviewing rheumatoid arthritis meds.
Pharma makes more from platinum pricing in the U.S. than it spends on research around the world, a new study shows.